Haemonetics Corporation (NYSE:HAE) was the recipient of a significant decline in short interest in the month of October. As of October 13th, there was short interest totalling 1,211,828 shares, a decline of 38.2% from the September 29th total of 1,960,751 shares. Based on an average daily volume of 333,615 shares, the days-to-cover ratio is presently 3.6 days. Approximately 2.3% of the shares of the company are sold short.

A number of research firms have commented on HAE. Zacks Investment Research raised shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research report on Wednesday, October 25th. Morgan Stanley reaffirmed an “equal weight” rating and set a $43.00 price objective (up from $38.00) on shares of Haemonetics Corporation in a research report on Friday, October 6th. TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Finally, Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.83.

Several institutional investors have recently made changes to their positions in the company. US Bancorp DE increased its position in shares of Haemonetics Corporation by 0.6% during the 2nd quarter. US Bancorp DE now owns 22,154 shares of the medical instruments supplier’s stock valued at $875,000 after purchasing an additional 141 shares during the last quarter. Tudor Investment Corp ET AL increased its holdings in Haemonetics Corporation by 0.5% in the 2nd quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock worth $1,111,000 after acquiring an additional 143 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in Haemonetics Corporation by 0.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock worth $845,000 after acquiring an additional 200 shares during the last quarter. Rothschild Asset Management Inc. increased its holdings in Haemonetics Corporation by 0.3% in the 2nd quarter. Rothschild Asset Management Inc. now owns 87,858 shares of the medical instruments supplier’s stock worth $3,470,000 after acquiring an additional 269 shares during the last quarter. Finally, Strs Ohio increased its holdings in Haemonetics Corporation by 1.0% in the 2nd quarter. Strs Ohio now owns 29,300 shares of the medical instruments supplier’s stock worth $1,157,000 after acquiring an additional 300 shares during the last quarter.

Haemonetics Corporation (NYSE:HAE) last announced its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The firm had revenue of $211.00 million during the quarter, compared to analyst estimates of $211.29 million. During the same period last year, the firm posted $0.25 EPS. The business’s revenue was up .5% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: “Haemonetics Corporation (HAE) Short Interest Down 38.2% in October” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/haemonetics-corporation-hae-short-interest-down-38-2-in-october/1674482.html.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.